In this trial, the inclusion criteria specified patients with type 2 diabetes with over 6.5% of HbA1c and risk factors for the progression of kidney disease, such as albuminuria, who were treated with renin-angiotensin system blockade; enrollment included approximately 60% patients with stage 3 CKD [17]. Here, REN is linked to type 2 diabetes mellitus.